Wallen, Z. D., Nesline, M. K., Tierno, M., Roos, A., Schnettler, E., Husain, H., . . . Ramkissoon, S. H. Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1. Frontiers Media S.A.
Chicago Style (17th ed.) CitationWallen, Zachary D., et al. Genomic Profiling of NSCLC Tumors with the TruSight Oncology 500 Assay Provides Broad Coverage of Clinically Actionable Genomic Alterations and Detection of Known and Novel Associations Between Genomic Alterations, TMB, and PD-L1. Frontiers Media S.A.
MLA (9th ed.) CitationWallen, Zachary D., et al. Genomic Profiling of NSCLC Tumors with the TruSight Oncology 500 Assay Provides Broad Coverage of Clinically Actionable Genomic Alterations and Detection of Known and Novel Associations Between Genomic Alterations, TMB, and PD-L1. Frontiers Media S.A.